Immune modulation with death receptor-induced apoptosis
AssigneeUniversity of Louisville Research Foundation, Inc.
InventorHaval Shirwan
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of Louisville Research Foundation, Inc.
InventorHaval Shirwan
Estimating the term…
This invention provides chimeric proteins comprising an apoptosis-inducing molecule fused to a member of a binding pair that is capable of binding to a selected cell that expresses a death receptor. When the selected cell is exposed in vivo or ex vivo to the chimeric protein, the selected cell undergoes apoptosis. The preferred embodiment is FasL protein fused to streptavidin. The methods of using the chimeric proteins are especially beneficial in causing activated lymphocytes to undergo apoptosis, thus modulating the immune response. Patients with conditions such as asthma or allergy, or patients undergoing transplantation with allogeneic or xenogeneic tissue are examples of patients who benefit from the methods of this invention.
A chimeric protein comprising an apoptosis-inducing protein fused to a member of a binding pair that is capable of binding to a selected cell expressing a death receptor.
A chimeric protein comprising an apoptosis-inducing protein fused to a member of a binding pair that is capable of binding to a selected cell expressing a death receptor.
Dependencies are inferred from the claim text.